The positive Phase 1 data de-risks the subcutaneous BRIUMVI program and supports the ongoing Phase 3 trial. Traders should monitor for Phase 3 topline results (late 2026/early 2027) and any device bridging study updates later this year. The potential for a self-administered quarterly anti-CD20 therapy could significantly expand TGTX's total addressable market, making this a key catalyst to watch.
Price Chart
Executive Summary
TG Therapeutics announced positive Phase 1 data for a subcutaneous formulation of BRIUMVI, showing favorable pharmacokinetics, safety, and tolerability. The quarterly subcutaneous dosing regimen achieved modeled non-inferior drug exposure vs. IV BRIUMVI, supporting the ongoing Phase 3 trial with topline data expected late 2026 or early 2027. If approved, subcutaneous BRIUMVI could be the first self-administered quarterly anti-CD20 therapy for MS, potentially nearly doubling the addressable market.
Key Facts
- Phase 1 trial of subcutaneous BRIUMVI showed mean bioavailability >60% vs. IV, with lower bound of 95% CI exceeding 55%.
- PK modeling supports non-inferior total drug exposure over 24 weeks for quarterly dosing (GMR 1.21, lower bound 90% CI 1.15) and every-other-month dosing (GMR 1.58, lower bound 90% CI 1.50), both exceeding the non-inferiority threshold of 0.80.
- Subcutaneous BRIUMVI was well-tolerated; local injection-site reactions occurred in <5% of patients, systemic injection-related reactions in ~21%, all resolved, no serious injection-site reactions or new safety signals.
- Phase 3 trial fully enrolled; topline results expected late 2026 or early 2027; potential approval in 2028 if successful.
- CEO stated subcutaneous option could nearly double the addressable market for the BRIUMVI franchise.
- Over 100 patients treated in Phase 1, including >80 receiving subcutaneous BRIUMVI across multiple dose levels; >225 subcutaneous injections administered, >75% at 400 mg (2 mL).
Financial Impact
No financial figures provided; potential market expansion from subcutaneous BRIUMVI could nearly double the BRIUMVI franchise addressable market if approved.
Risk Factors
- Phase 3 trial may fail to meet primary endpoint despite positive Phase 1 data.
- Regulatory approval not guaranteed; timeline to potential approval in 2028 is subject to delays or rejection.
- Commercial adoption of subcutaneous BRIUMVI may be lower than anticipated, limiting market expansion.
- Competition from existing and emerging MS therapies could erode market share.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3305943 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 3, 2026 12w ago | 8-K | $46.17 | awaiting T+60 | — | $55.92 (+21.12%) |
Jun 11, 2026 19w ago | Institutional Cluster | $49.52 $55.74 | ▲ +12.56% | ▲ +9.30% | $55.92 (+12.92%) |
Jun 3, 2026 20w ago | 8-K | $40.11 $55.72 | ▲ +38.92% | ▲ +36.42% | $55.92 (+39.42%) |
Jun 3, 2026 20w ago | Press Release | $40.11 $55.72 | ▲ +38.92% | ▲ +36.42% | $55.92 (+39.42%) |
Jun 1, 2026 21w ago | Press Release | $37.41 $55.42 | ▲ +48.14% | ▲ +46.91% | $55.92 (+49.48%) |
May 27, 2026 21w ago | 8-K | $38.82 $54.27 | ▲ +39.80% | ▲ +38.06% | $55.92 (+44.05%) |
May 6, 2026 24w ago | 8-K | $41.97 $52.03 | ▲ +23.97% | ▲ +21.91% | $55.92 (+33.24%) |
Apr 30, 2026 25w ago | Press Release | $33.78 $55.75 | ▲ +65.04% | ▲ +61.93% | $55.92 (+65.54%) |
Apr 22, 2026 26w ago | Press Release | $38.31 $54.87 | ▲ +43.23% | ▲ +38.45% | $55.92 (+45.97%) |
Apr 15, 2026 27w ago | Press Release | $34.60 $57.12 | ▲ +65.09% | ▲ +56.95% | $55.92 (+61.62%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers